Article Details

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

Retrieved on: 2022-06-16 19:42:35

Tags for this article:

Click the tags to see associated articles and topics

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence. View article details on HISWAI: https://www.onclive.com/view/onilcamotide-fails-to-reduce-risk-of-progression-in-prostate-cancer-with-biochemical-recurrence

Excerpt

... with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.

Article found on: www.onclive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up